Literature DB >> 23740195

Setting the record straight on TIDE: a lost opportunity for patients with diabetes.

Zubin Punthakee1, Jackie Bosch, Hertzel C Gerstein.   

Abstract

Much has been written regarding the recently discontinued Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE) trial (ClinicalTrials.gov NCT00879970; Diabetologia 55: 36-45) and a variety of opinions have been advanced regarding its purpose, context and design (N Engl J Med 397: 959-964). As such, we deemed it appropriate to clarify TIDE's objectives, research questions and design and the clinical equipoise regarding its research questions.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23740195     DOI： 10.1007/s00125-013-2959-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


  41 in total

1.  Review: rosiglitazone increases risk of MI but does not differ from other drugs for CV death in type 2 diabetes.

Authors:  Mark A Hlatky; Dena M Bravata
Journal:  Evid Based Med       Date:  2007-12

Review 2.  Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.

Authors:  Pantelis A Sarafidis; Panagiotis C Stafylas; Panagiotis I Georgianos; Athanasios N Saratzis; Anastasios N Lasaridis
Journal:  Am J Kidney Dis       Date:  2010-01-29       Impact factor: 8.860

3.  Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

Authors:  Theodore Mazzone; Peter M Meyer; Steven B Feinstein; Michael H Davidson; George T Kondos; Ralph B D'Agostino; Alfonso Perez; Jean-Claude Provost; Steven M Haffner
Journal:  JAMA       Date:  2006-11-13       Impact factor: 56.272

4.  Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.

Authors:  Silvio E Inzucchi; Frederick A Masoudi; Yongfei Wang; Mikhail Kosiborod; Joanne M Foody; John F Setaro; Edward P Havranek; Harlan M Krumholz
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

Review 5.  The calcium channel blocker controversy in perspective.

Authors:  A Zanchetti
Journal:  Cardiology       Date:  1997       Impact factor: 1.869

6.  Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death.

Authors:  Jonathan J Shuster; Lynn S Jones; Daniel A Salmon
Journal:  Stat Med       Date:  2007-10-30       Impact factor: 2.373

7.  Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.

Authors:  Meng Tan; Don Johns; Guillermo González Gálvez; Oscar Antúnez; Guadalupe Fabián; Fernando Flores-Lozano; Sergio Zúñiga Guajardo; Eduardo Garza; Hector Morales; Christopher Konkoy; Matthias Herz
Journal:  Clin Ther       Date:  2004-05       Impact factor: 3.393

8.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

9.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Authors:  Steven E Nissen; Stephen J Nicholls; Kathy Wolski; Richard Nesto; Stuart Kupfer; Alfonso Perez; Horacio Jure; Robert De Larochellière; Cezar S Staniloae; Kreton Mavromatis; Jacqueline Saw; Bo Hu; A Michael Lincoff; E Murat Tuzcu
Journal:  JAMA       Date:  2008-03-31       Impact factor: 56.272

10.  Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

Authors:  Ioanna Tzoulaki; Mariam Molokhia; Vasa Curcin; Mark P Little; Christopher J Millett; Anthea Ng; Robert I Hughes; Kamlesh Khunti; Martin R Wilkins; Azeem Majeed; Paul Elliott
Journal:  BMJ       Date:  2009-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.